EGFR and non-small cell lung carcinoma: (105) discovered that for 169 advanced NSCLC patients who harbored EGFR-sensitive mutations treated with EGFR-TKIs, patients with concurrent PTEN deletion had a shorter PFS and OS than those with intact PTEN (HR for PFS, 3.64; 95% CI, 1.47–9.00; HR for OS, 2.86; 95% CI, 1.04–7.89).